Recent Blog Articles

Heart Beat: Trial Watch

Updated: October 01, 2009

Heart Beat

Trial Watch

Welcome to the first installment of Trial Watch. In this occasional feature, we will highlight important nationwide clinical trials that are in need of participants.

CLEVER. The Claudication: Exercise Versus Endoluminal Revascularization Study is tackling a key question that could help some of the millions of people with peripheral artery disease: What is the best way to treat leg pain that occurs with walking (a condition known as claudication)? There are currently three main options for those afflicted by this aggravating and sometimes disabling condition. These include exercise at home plus drug therapy, supervised exercise therapy plus drug therapy, and placement of an artery-opening stent. In CLEVER, volunteers with claudication will be randomly assigned to one of these three options or a fourth one — stent placement plus supervised exercise and drug therapy. The researchers will measure the effectiveness, safety, cost, and overall economic impact of the four strategies. The trial is being conducted at 30 hospitals across the country.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».


As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.